- Zacks•8 hours ago
Shire plc (SHPG) announced that the FDA has granted Fast Track designation for recombinant ADAMTS13 (SHP655) for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP).
- Investopedia•2 days ago
Shire is planning a late-stage study for its SHP655 drug to treat a rare enzyme deficiency.
- PR Newswire•2 days ago
Shire Receives FDA Fast Track Designation for Recombinant ADAMTS13 (SHP655) for Treatment of Hereditary Thrombotic Thrombocytopenic Purpura
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for recombinant ADAMTS13 (SHP655 - historically known as BAX930) for treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP) in patients with a constitutional deficiency of the von Willebrand factor-cleaving (VWF) protease ADAMTS13. FDA's Fast Track designation is supported by preclinical data and a Phase 1 study.
SHPG : Summary for Shire plc - Yahoo Finance
Shire plc (SHPG)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Ask||200.00 x 100|
|Day's Range||173.56 - 175.40|
|52 Week Range||161.09 - 209.22|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||140.11|
|Dividend & Yield||0.91 (0.53%)|
|1y Target Est||N/A|